Evidence map›Paper›PMID 38575948›Full record

ArticleBMC public health2024

Evaluation of a population-wide, systematic screening initiative for tuberculosis on Daru island, Western Province, Papua New Guinea.

Paison Dakulala, Margaret Kal, Alice Honjepari, Lucy Morris, Richard Rehan, Simon Peter Akena, Andrew J Codlin, Narantuya Jadambaa, Tauhid Islam, Manami Yanagawa and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 4 countries.

Paison Dakulala *National Department of Health, Port Moresby, Papua New Guinea.
Margaret KalNational Department of Health, Port Moresby, Papua New Guinea.
Alice HonjepariWestern Provincial Health Authority, Daru, Papua New Guinea.
Lucy MorrisWestern Provincial Health Authority, Daru, Papua New Guinea.
Richard Rehan *World Health Organization Representative Office for Papua New Guinea, Port Moresby, Papua, New, Guinea.
Simon Peter AkenaWorld Vision International, Stop TB Programme, Daru, Papua New Guinea.
Andrew J CodlinFriends for International TB Relief (FIT), Ho Chi Minh City, Viet Nam.
Narantuya JadambaaWorld Health Organization Representative Office for Papua New Guinea, Port Moresby, Papua, New, Guinea.
Tauhid IslamGlobal Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
Manami YanagawaWorld Health Organization Regional Office for the Western Pacific, Manila, Philippines.
Fukushi MorishitaWorld Health Organization Regional Office for the Western Pacific, Manila, Philippines. morishitaf@who.int.
National Department of Health · PGUniversity of Papua New Guinea · PGWorld Health Organization Regional Office for the Western Pacific · PHKarolinska Institutet · SEWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundA population-wide, systematic screening initiative for tuberculosis (TB) was implemented on Daru island in the Western Province of Papua New Guinea, where TB is known to be highly prevalent. The initiative used a mobile van equipped with a digital X-ray device, computer-aided detection (CAD) software to identify TB-related abnormalities on chest radiographs, and GeneXpert machines for follow-on diagnostic testing. We describe the results of the TB screening initiative, evaluate its population-level impact and examine risk factors associated with TB detection.

methodsThrough a retrospective review of screening data, we assessed the effectiveness of the screening by examining the enrolment coverage and the proportion of people with TB among screened subjects. A cascade analysis was performed to illustrate the flow of participants in the screening algorithm. We conducted univariate and multivariate analyses to identify factors associated with TB. Furthermore, we estimated the number of additional cases detected by the project by examining the trend of routine TB case notifications during the intervention period, compared to the historical baseline cases and trend-adjusted expected cases.

resultsOf the island's 18,854 residents, 8,085 (42.9%) were enrolled and 7,970 (98.6%) had chest X-ray interpreted by the CAD4TB software. A total of 1,116 (14.0%) participants were considered to have abnormal CXR. A total of 69 Xpert-positive cases were diagnosed, resulting in a detection rate of 853 per 100 000 population screened. 19.4% of people with TB had resistance to rifampicin. People who were in older age groups (aOR 6.6, 95%CI: 1.5-29.1 for the 45-59 age group), were severely underweight (aOR 2.5, 95%CI:1.0-6.1) or underweight (aOR 2.1, 95%CI: 1.1-3.8), lived in households < 5 people (aOR 3.4, 95%CI:1.8-6.6) and had a past history of TB (aOR 2.1, 95%CI: 1.2-3.6) were more likely to have TB. The number of bacteriologically confirmed TB notified during the intervention period was 79.3% and 90.8% higher than baseline notifications and forecasted notifications, respectively.

conclusionThe screening project demonstrated its effectiveness with the high Xpert-positive TB prevalence among the participants and by successfully yielding additional cases of bacteriologically confirmed TB including rifampicin-resistant TB. The results and lessons learnt from the project should inform future TB screening initiatives in Papua New Guinea.

Indexed as

TuberculosisTuberculosis, Multidrug-ResistantAgedHumansMass ScreeningPapua New GuineaRifampinThinnessRifampinPapua New GuineaScreeningTuberculosis

Identifiers

PMID38575948
PMCPMC10993525
OpenAlexW4393935356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.